1-8 of 8
Alison M. Schram
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A. Boezio, Artemisa Bulku, Lucian DiPietro, Cary Fridrich, Adam Frost, Fabrizio Giordanetto, Erika P. Hamilton, Katherine Harris, Michael Holliday, Tamieka L. Hunter, Amanda Iskandar, Yongli Ji, Alexandre Larivée, Jonathan R. LaRochelle, André Lescarbeau, Fabien Llambi, Brenda Lormil, Mary M. Mader, Brenton G. Mar, Iain Martin, Thomas H. McLean, Klaus Michelsen, Yakov Pechersky, Erika Puente-Poushnejad, Kevin Raynor, Dipali Rogala, Ramin Samadani, Alison M. Schram, Kelley Shortsleeves, Sweta Swaminathan, Shahein Tajmir, Gege Tan, Yong Tang, Roberto Valverde, Bryan Wehrenberg, Jeremy Wilbur, Bret R. Williams, Hongtao Zeng, Hanmo Zhang, W. Patrick Walters, Beni B. Wolf, David E. Shaw, Donald A. Bergstrom, James Watters, James S. Fraser, Pascal D. Fortin, D. Randal Kipp
Journal: Cancer Discovery
Cancer Discov (2024) 14 (2): 240–257.
https://doi.org/10.1158/2159-8290.CD-23-0944
Published: 08 February 2024
View article titled, Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Open the PDF for Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia in another window
Includes: Supplementary data
Journal Articles

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B. Barry Touré, Songping Zhao, Roberto Valverde, Patrick J. O'Hearn, Demetri T. Moustakas, Heike Schönherr, Nastaran Gerami-Moayed, Alexander M. Taylor, Brandi M. Hudson, Damian J. Houde, Debjani Pal, Lindsey Foster, Hakan Gunaydin, Pelin Ayaz, Dina A. Sharon, Lipika Goyal, Alison M. Schram, Suneel Kamath, Cori Ann Sherwin, Oleg Schmidt-Kittler, Kai Yu Jen, Fabien Ricard, Beni B. Wolf, David E. Shaw, Donald A. Bergstrom, James Watters, Jessica B. Casaletto
Journal: Cancer Discovery
Cancer Discov (2023) 13 (9): 2012–2031.
https://doi.org/10.1158/2159-8290.CD-23-0475
Published: 06 September 2023
View article titled, RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <em>FGFR2</em> Alterations and Resistance Mutations
Open the PDF for RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <em>FGFR2</em> Alterations and Resistance Mutations in another window
Includes: Multimedia, Supplementary data
Journal Articles

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Alison M. Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar, Allan J.W. Lui, Morana Vojnic, Sara H. Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N. O'Connor, Cecile A.W. Geuijen, Ron C.J. Schackmann, Jeroen J. Lammerts van Bueren, Ernesto Wasserman, Elisa de Stanchina, Eileen M. O'Reilly, Marc Ladanyi, Alexander Drilon, Romel Somwar
Journal: Cancer Discovery
Cancer Discov (2022) 12 (5): 1233–1247.
https://doi.org/10.1158/2159-8290.CD-21-1119
Published: 02 May 2022
View article titled, Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by <em>NRG1</em> Gene Rearrangements
Open the PDF for Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by <em>NRG1</em> Gene Rearrangements in another window
Includes: Supplementary data
Journal Articles

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen H. Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena, Srushti Kittane, Fan Wu, Yanyan Cai, Sabrina Arena, Benedetta Mussolin, Ram Kannan, Neil Vasan, Alexander N. Gorelick, Michael F. Berger, Ofra Novoplansky, Sankar Jagadeeshan, Yi Liao, Uwe Rix, Sandra Misale, Barry S. Taylor, Alberto Bardelli, Jaclyn F. Hechtman, David M. Hyman, Moshe Elkabets, Elisa de Stanchina, Chandra S. Verma, Andrea Ventura, Alexander Drilon, Maurizio Scaltriti
Journal: Cancer Discovery
Cancer Discov (2021) 11 (1): 126–141.
https://doi.org/10.1158/2159-8290.CD-20-0571
Published: 06 January 2021
View article titled, TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
Open the PDF for TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Lillian M. Smyth, Sarina A. Piha-Paul, Helen H. Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos L. Arteaga, Macarena I. de la Fuente, Adam M. Brufksy, Iben Spanggaard, Morten Mau-Sørensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S. Schwartzberg, Xavier Gonzàlez-Farré, Andrés Cervantes, François-Clement Bidard, Alexander N. Gorelick, Richard B. Lanman, Rebecca J. Nagy, Gary A. Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I. Gavrila, Catherine Zimel, S. Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D. Eli, Melanie Dujka, Alshad S. Lalani, Richard Bryce, José Baselga, Barry S. Taylor, David B. Solit, Funda Meric-Bernstam, David M. Hyman
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (2): 198–213.
https://doi.org/10.1158/2159-8290.CD-19-0966
Published: 05 February 2020
View article titled, Efficacy and Determinants of Response to HER Kinase Inhibition in <em>HER2</em>-Mutant Metastatic Breast Cancer
Open the PDF for Efficacy and Determinants of Response to HER Kinase Inhibition in <em>HER2</em>-Mutant Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Accelerating Discovery of Functional Mutant Alleles in Cancer

Matthew T. Chang, Tripti Shrestha Bhattarai, Alison M. Schram, Craig M. Bielski, Mark T.A. Donoghue, Philip Jonsson, Debyani Chakravarty, Sarah Phillips, Cyriac Kandoth, Alexander Penson, Alexander Gorelick, Tambudzai Shamu, Swati Patel, Christopher Harris, JianJiong Gao, Selcuk Onur Sumer, Ritika Kundra, Pedram Razavi, Bob T. Li, Dalicia N. Reales, Nicholas D. Socci, Gowtham Jayakumaran, Ahmet Zehir, Ryma Benayed, Maria E. Arcila, Sarat Chandarlapaty, Marc Ladanyi, Nikolaus Schultz, José Baselga, Michael F. Berger, Neal Rosen, David B. Solit, David M. Hyman, Barry S. Taylor
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (2): 174–183.
https://doi.org/10.1158/2159-8290.CD-17-0321
Published: 04 February 2018
View article titled, Accelerating Discovery of Functional Mutant Alleles in Cancer
Open the PDF for Accelerating Discovery of Functional Mutant Alleles in Cancer in another window
Includes: Supplementary data
Journal Articles

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake, Nora Ku, Brian B. Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Paul D. Larsen, Karyn S. Bouhana, Shannon L. Winski, Robyn Hamor, Wen-I Wu, Andrew Parker, Tony H. Morales, Francis X. Sullivan, Walter E. DeWolf, Lance A. Wollenberg, Paul R. Gordon, Dorothea N. Douglas-Lindsay, Maurizio Scaltriti, Ryma Benayed, Sandeep Raj, Bethany Hanusch, Alison M. Schram, Philip Jonsson, Michael F. Berger, Jaclyn F. Hechtman, Barry S. Taylor, Steve Andrews, S. Michael Rothenberg, David M. Hyman
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (9): 963–972.
https://doi.org/10.1158/2159-8290.CD-17-0507
Published: 31 August 2017
View article titled, A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
Open the PDF for A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Quantifying the Benefits of Genome-Driven Oncology

Alison M. Schram, David M. Hyman
Journal: Cancer Discovery
Cancer Discov (2017) 7 (6): 552–554.
https://doi.org/10.1158/2159-8290.CD-17-0380
Published: 01 June 2017
View article titled, Quantifying the Benefits of Genome-Driven Oncology
Open the PDF for Quantifying the Benefits of Genome-Driven Oncology in another window